Filana Therapeutics Inc 's ROA from the first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Filana Therapeutics Inc 's ROA in the first quarter of 2026?
Filana Therapeutics Inc recorded a cumulative net loss of $-78 million during 12 months ending in the first quarter of 2026, resulting in a negative return on assets (ROA) of -63.35%.

However, within the Healthcare sector 633 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Mar 31 2026 quarter, so far to 4062, from total ROA ranking in the fourth quarter of 2025 at 4795.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter	(Mar 31 2025) I. Quarter
Y / Y Total Assets Change	-23.11 %	-24.87 %	-42.02 %	-44.42 %	-9.5 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-78	-91	-106	-123	-73
Return On Assets (TTM)	-63.35 %	-69.39 %	-75.25 %	-74.92 %	-38.02 %
FLNA's Total Ranking	# 4062	# 4795	# 4245	# 4304	# 3989
Total Assets (TTM) in million	108	118	130	135	141
Seq. Total Assets Change	-8.44 %	-8.77 %	-4.17 %	-3.94 %	-10.54 %
Seq. Net Income Change	-	-	-	-	-

FLNA's 5 Years Annual ROA >> Back to FLNA Management Effectiveness >> Compare FLNA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 286
Sector	# 634
Overall	# 4027

Return On Assets Statistics
High	Average	Low
60.1 %	-28.54 %	-93.36 %
(Dec 31 2013)		(Mar 31 2018)

Financial Statements
Filana Therapeutics Inc 's Assets	$ 108 million	FLNA's Balance sheet
Filana Therapeutics Inc 's Income	$ -10 million	Quarterly FLNA's Income Statement
FLNA's Income by Division		See FLNA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-24.87 %	3.87 %	-35.42 %	-11.98 %	182.91 %
Total Assets in million	118	158	152	235	267
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-91	19	-97	-76	-32
Annual Return On Assets	-76.86 %	12.35 %	-64.1 %	-32.47 %	-12.14 %

FLNA's 5 Years Annual ROA >> Back to FLNA Management Effectiveness >> Compare FLNA ROA to its Competitors

More Return On Assets Ratios
FLNA's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
FLNA's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for FLNA's Competitors
Subscribers only: Roa for Filana Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for FLNA's Customers

You may also want to know
FLNA's Roi	FLNA's Inventory Turnover Ratio	FLNA's Growth Rates	FLNA's Dividend Comparisons
	FLNA's Profitability Ratios	FLNA's Asset Turnover Ratio	FLNA's Dividend Growth
FLNA's Roe	FLNA's Valuation Ratios	FLNA's Financial Strength Ratios	FLNA's Dividend Payout Ratio

Companies with similar Return On Assets at Mar 31 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T17:42:48+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.